New RSV antibody shows promise for vulnerable babies in japan

NCT ID NCT06042049

First seen Apr 26, 2026 · Last updated May 15, 2026 · Updated 4 times

Summary

This study tested a medicine called nirsevimab in 33 Japanese infants under 1 year old who have health problems like heart or lung disease, weak immune systems, Down syndrome, or were born early. The goal was to see if two doses given 5-6 months apart are safe and help protect against RSV, a serious respiratory virus. The study is complete and focused on safety and how the body responds to the medicine.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Bunkyō City, 113-8519, Japan

  • Research Site

    Fuchu-shi, 183-8561, Japan

  • Research Site

    Fukuoka, 813-0017, Japan

  • Research Site

    Kitakyusyu-shi, 806-8501, Japan

  • Research Site

    Kōtoku, 135-8577, Japan

  • Research Site

    Kurume-shi, 830-0011, Japan

  • Research Site

    Nagasaki, 852-8501, Japan

  • Research Site

    Saitama-shi, 336-8522, Japan

  • Research Site

    Yokohama, 232 8555, Japan

Conditions

Explore the condition pages connected to this study.